Sign In
Buy VRTX
$428.34
+3.25 (+0.765%)
At Close: Jun 03, 2026
Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings?
10:55am, Wednesday, 05'th Feb 2025
On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza triple) and Journavx (suzetrigine).
Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics
10:21am, Wednesday, 05'th Feb 2025
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qua
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ
VRTX STOCK ALERT: Levi & Korsinsky Notifies Vertex Pharmaceuticals Incorporated Investors of an Ongoing Investigation
07:30am, Tuesday, 04'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
07:10am, Tuesday, 04'th Feb 2025
Vertex Pharmaceuticals (VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings. But Ve
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
06:56pm, Monday, 03'rd Feb 2025
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $470.37, marking a +1.88% move from the previous day.
Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?
10:05am, Monday, 03'rd Feb 2025
Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:51am, Monday, 03'rd Feb 2025
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
3 Magnificent Stocks to Buy and Hold Forever
09:30am, Monday, 03'rd Feb 2025
Some people are fair-weather friends; others are lifelong. It's a similar story with stocks.
Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?
08:45am, Monday, 03'rd Feb 2025
Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.
Lost Money on Vertex Pharmaceuticals Incorporated(VRTX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
07:30am, Monday, 03'rd Feb 2025
NEW YORK, NY / ACCESS Newswire / February 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
08:06am, Sunday, 02'nd Feb 2025
Vertex Pharmaceuticals (VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
05:35am, Sunday, 02'nd Feb 2025
Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (VRTX 5.31%) are down about 9% from a peak the stock set in November, d
Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain
10:17pm, Saturday, 01'st Feb 2025
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges: variable efficacy vs opioids, generic competition, and entrenched prescriber habits limit near-term potential. Phase 2
Vertex: YOY Decline In Q4 Earnings Expected, But Revenue Continues To Shine
08:00am, Saturday, 01'st Feb 2025
Expectation is a decline in Vertex's earnings, but double-digit revenue growth should continue with the newly approved non-opioid drug JOURNAVX and CF franchise expansion. JOURNAVX, the first non-opio
